PTPoonam Tewary

Poonam Tewary

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Poonam Tewary has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:

  • De Yang

    Laboratory of Molecular Immunoregulation, Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, Laboratory for Cancer Research , Frederick, MD 21702

    4 shared publications
  • Gonzalo de la Rosa

    Laboratory of Molecular Immunoregulation, Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, Laboratory for Cancer Research , Frederick, MD 21702

    3 shared publications
  • Joost J. Oppenheim

    Laboratory of Molecular Immunoregulation, Cancer and Inflammation Program, Center for Cancer Research, Frederick National Laboratory for Cancer Research (FNLCR), Frederick, Maryland

    2 shared publications
  • A. Dimitrios Colevas

    Stanford University School of Medicine

    1 shared publication
  • Abu Z. Saeed

    University of Birmingham

    1 shared publication
  • Ada Chen

    1 shared publication

Latest Publications

  • Open Access

    31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

    by Casey Ager, Matthew Reilley, Courtney Nicholas, Todd Bartkowiak, Ashvin Jaiswal, Michael Curran, Tina C. Albershardt, Anshika Bajaj, Jacob F. Archer, Rebecca S. Reeves, et al.


  • Using natural products to promote caspase-8-dependent cancer cell death

    by Poonam Tewary, A. A. Leslie Gunatilaka, Thomas J. Sayers

    The selective killing of cancer cells without toxicity to normal nontransformed cells is an idealized goal of cancer therapy. Thus, there has been much interest in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), a protein that appears to selectively kill cancer cells. TRAIL has been reported to trigger apoptosis and under some circumstances, an alternate death signaling pathway termed necroptosis. The relative importance of necroptosis for cell death induction in vivo is under intensive investigation. Nonetheless, many cancer cells (particularly those freshly isolated from cancer patients) are highly resistant to TRAIL-mediated cell death. Therefore, there is an underlying interest in identifying agents that can be combined with TRAIL to improve its efficacy. There are numerous reports in which combination of TRAIL with standard antineoplastic drugs has resulted in enhanced cancer cell death in vitro. However, many of these chemotherapeutic drugs are nonspecific and associated with adverse effects, which raise serious concerns for cancer therapy in patients. By contrast, natural products have been shown to be safer and efficacious alternatives. Recently, a number of studies have suggested that certain natural products when combined with TRAIL can enhance cancer cell death. In this review, we highlight molecular pathways that might be targeted by various natural products to promote cell death, and focus on our recent work with withanolides as TRAIL sensitizers. Finally, we will suggest synergistic approaches for combining active withanolides with various forms of immunotherapy to promote cancer cell death and an effective antitumor immune response.


  • β-Defensin 2 and 3 Promote the Uptake of Self or CpG DNA, Enhance IFN-α Production by Human Plasmacytoid Dendritic Cells, and Promote Inflammation

    by Poonam Tewary, Gonzalo de la Rosa, Neeraj Sharma, Luis G. Rodriguez, Sergey G. Tarasov, O. M. Zack Howard, Hidekazu Shirota, Folkert Steinhagen, Dennis M. Klinman, De Yang, et al.

    Alarmins are a group of structurally diverse host defense antimicrobial peptides that are important immune activators. In this article, we present a novel role for two potent alarmins, human β-defensin 2 and 3 (HBD2 and 3), in promoting IFN-α production by human plasmacytoid dendritic cells. We demonstrate that HBD2 and 3 activate pDCs by enhancing the intracellular uptake of CpG and self DNA and promote DNA-induced IFN-α production in a TLR9-dependent manner. Both CpG and host DNA form aggregates that resemble DNA nets when combined with HBD2 and 3. Isothermal titration calorimetry studies to elucidate the nature of HBD3/CpG complexes demonstrate involvement of enthalpy-driven interactions, in addition to hydrophobic interactions, with the formation of complexes at a molar ratio of 2:1 defensin/CpG. The i.v. administration of HBD3/CpG complexes induced proinflammatory cytokines like IL-12, IFN-γ, IL-6, IFN-α, and IL-10 in serum, associated with an increased recruitment of APCs in the spleen. Subcutaneous injections of these complexes showed enhanced infiltration of inflammatory cells at the injection site, indicating a potential pathophysiological role for alarmin/DNA complexes in contributing to inflammation. Intraperitoneal immunization of HBD3/CpG complexes with OVA enhanced both cellular and humoral responses to OVA, compared with OVA/HBD3 or OVA/CPG alone, indicative of a much more potent adjuvant effect of the HBD3/CpG complexes. Thus, the ability of defensins to enhance cellular uptake of nucleic acids can lead to improved vaccine formulations by promoting their uptake by various cells, resulting in an enhanced immune response.


  • CS10-7 Effect of antimicrobial proteins/alarmins on DNA mediated activation of pDC and inflammation

    by Poonam Tewary, Gonzalo la Rosa, Neeraj Sharma, Luis Rodriguez, Hidekatzu Shirota, Folkert Steinhagen, Dennis M. Klinman, De Yang, Joost J. Oppenheim

  • PS1-12 Alarmins activate immune responses by inducing dendritic cell chemotaxis and maturation

    by Joost J. Oppenheim, Poonam Tewary, Gonzalo de la Rosa, De Yang

  • Open Access

    Granulysin activates antigen-presenting cells through TLR4 and acts as an immune alarmin

    by Poonam Tewary, De Yang, Gonzalo de la Rosa, Yana Li, Michael W. Finn, Alan M. Krensky, Carol Clayberger, Joost J. Oppenheim

    Granulysin (GNLY), an antimicrobial protein present in the granules of human cytotoxic T lymphocytes and natural killer (NK) cells, is produced as an intact 15-kDa form that is cleaved to yield a 9-kDa form. Alarmins are endogenous mediators that can induce recruitment and activation of antigen-presenting cells (APCs) and consequently promote the generation of immune response. We hypothesized that GNLY might function as an alarmin. Here, we report that both 9- and 15-kDa forms of recombinant GNLY-induced in vitro chemotaxis and activation of both human and mouse dendritic cells (DCs), recruited inflammatory leucocytes, including APCs in mice, and promoted antigen-specific immune responses upon coadministration with an antigen. GNLY-induced APC recruitment and activation required the presence of Toll-like receptor 4. The observed activity of recombinant GNLY was not due to endotoxin contamination. The capability of the supernatant of GNLY-expressing HuT78 cells to activate DC was blocked by anti-GNLY antibodies. Finally we present evidence that supernatants of degranulated human NK92 or primary NK cells also activated DCs in a GNLY- and Toll-like receptor 4–dependent manner, indicating the physiologic relevance of our findings. Thus, GNLY is the first identified lymphocyte-derived alarmin capable of promoting APC recruitment, activation, and antigen-specific immune response.